Assay method for detecting 5-HT2B antagonists
AssigneePharmagene Laboratories Limited
InventorsRichard A. Borman, Nicholas S. Tilford, Gordon S. Baxter
Life of this patent
Estimating the term…
Loading patent…
AssigneePharmagene Laboratories Limited
InventorsRichard A. Borman, Nicholas S. Tilford, Gordon S. Baxter
Estimating the term…
The present invention relates to the finding that receptors for the neurotransmitter 5-HT of the 5-HT2B class are located on the human colon, and that their activation potentiates neuronally-mediated responses, and are thus causative in the abnormal motility and pain associated with IBS. The invention provides a method of treatment of IBS which comprises providing to a patient in need of treatment an effective amount of a 5HT2B receptor antagonist which acts on 5HT2B receptors located in the colon of said patient. Such antagonists may be administered in the form of compositions adapted to be delivered to the colon, such as depot formulations and suppositories. Assay methods for the development of compounds for the treatment of IBS are also provided.
An assay to determine whether or not a compound is capable of antagonising 5-HT2B receptor activity, which assay comprises determining whether or not said compound is capable of antagonising said activity in the human colon.
Dependencies are inferred from the claim text.